Antibody Drug Conjugate (ADC) Drug Market was valued at USD 5.1 Billion in 2022 and is projected to reach USD 14.3 Billion by 2030, growing at a CAGR of 13.8% from 2024 to 2030.
In terms of demand, from 2023 to 2033, the ADC drug market is poised for further expansion. The growing trend towards personalized medicine, along with ongoing research into new and improved ADC formulations, is expected to fuel the market. According to forecasts, the market is anticipated to grow at a compound annual growth rate (CAGR) of approximately 15-18% over the next decade. Key factors driving this demand include the rising prevalence of cancer globally, breakthroughs in the understanding of cancer genomics, and the increasing application of ADCs in various oncology indications. The entry of new players into the ADC space, alongside the launch of novel technologies such as site-specific conjugation methods, is expected to enhance the therapeutic value of ADCs.
With greater collaboration between biotech firms and pharmaceutical companies, the pipeline for ADCs is robust, with several candidates in late-stage clinical trials. This shift is expected to drive the market’s growth in the coming years, further expanding its applications beyond oncology. As regulatory pathways become clearer and more favorable for ADCs, coupled with the development of ADCs targeting solid tumors and hematologic cancers, market opportunities will likely see a dramatic increase.
Get an In-Depth Research Analysis of the Global Antibody Drug Conjugate (ADC) Drug Market Size And Forecast [2025-2032]
The Antibody Drug Conjugate (ADC) drug market has seen significant growth between 2018 and 2022, driven by advancements in biotechnology, increasing investments, and the rising demand for targeted cancer therapies. ADCs, which link antibodies to cytotoxic drugs, have revolutionized oncology treatments by offering precision-targeted therapies with reduced side effects compared to traditional chemotherapy. This period witnessed key developments in the clinical success of ADCs, such as the FDA approval of several groundbreaking drugs like Kadcyla and Enhertu. These therapies not only demonstrated impressive efficacy but also expanded the ADC market’s potential, particularly for treating hard-to-treat cancers like breast cancer, non-Hodgkin’s lymphoma, and ovarian cancer.
Oxford Bio Therapeutics
Synthon
Progenics Pharmaceuticals
Bayer HealthCare
Millennium Pharmaceuticals
Pfizer
Concortis Bio therapeutics
Roche Holding AG
Seattle Genetics
Heidelberg Pharma
Mersana Therapeutics
Astellas Pharma/Agensys
AbbVie Inc
Celldex Therapeutics
Immunomedics
Agensys
Genentech
ImmunoGen
Sanofi
Genmab
Amgen
Novartis
Eli Lilly
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Antibody Drug Conjugate (ADC) Drug Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global Antibody Drug Conjugate (ADC) Drug Market
Biotechnology Companies
Specialized Cancer Centers
Biopharmaceutical Companies
Academic Research Institutes
Hospitals
Others
Based on Types the Market is categorized into Below types that held the largest Antibody Drug Conjugate (ADC) Drug market share In 2023.
by Technology
Mmunomedics Technology
Immunogen Technology
Seattle Genetics Technology
Others
by Product Type
Kadcyla
Adcertis
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Antibody Drug Conjugate (ADC) Drug Market Research Analysis
1. Introduction of the Global Antibody Drug Conjugate (ADC) Drug Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Antibody Drug Conjugate (ADC) Drug Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Antibody Drug Conjugate (ADC) Drug Market, By Type
6. Global Antibody Drug Conjugate (ADC) Drug Market, By Application
7. Global Antibody Drug Conjugate (ADC) Drug Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global Antibody Drug Conjugate (ADC) Drug Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/